Fig. 1From: Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trialEQ-5D-5L data for patients in the PROMelanoma study at baseline, week 24 and week 48, comparing the HRQoL between patients assigned to the ePRO intervention and patients who received standard careBack to article page